Valion Bio's New Chairman Discusses Strategy & Entolimod
Valion Bio appointed Thomas Jensen as Board Chair and outlined his perspectives on advancing Entolimod, emphasizing the company's strong foundation and the lack of approved treatments for acute radiation syndrome.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed